ZA201002690B - N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors - Google Patents
N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitorsInfo
- Publication number
- ZA201002690B ZA201002690B ZA2010/02690A ZA201002690A ZA201002690B ZA 201002690 B ZA201002690 B ZA 201002690B ZA 2010/02690 A ZA2010/02690 A ZA 2010/02690A ZA 201002690 A ZA201002690 A ZA 201002690A ZA 201002690 B ZA201002690 B ZA 201002690B
- Authority
- ZA
- South Africa
- Prior art keywords
- hepatitis
- useful
- hcv
- hydropyrimidines
- dioxo
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97288707P | 2007-09-17 | 2007-09-17 | |
| US9679408P | 2008-09-13 | 2008-09-13 | |
| PCT/US2008/076594 WO2009039135A1 (en) | 2007-09-17 | 2008-09-17 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201002690B true ZA201002690B (en) | 2015-12-23 |
Family
ID=40091991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/02690A ZA201002690B (en) | 2007-09-17 | 2010-04-16 | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8178548B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2377854A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5726527B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN101918369B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE512954T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2699989C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2203430T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20110632T1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010002904A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2203430T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2203430E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2542099C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009039135A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201002690B (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2014147354A (ru) | 2007-09-17 | 2015-07-10 | Эббви Бахамаз Лтд. | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения |
| CN101918369B (zh) * | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| CA2736472A1 (en) | 2008-09-26 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyrine or pyrazine derivatives for treating hcv |
| CA2741325A1 (en) | 2008-10-30 | 2010-05-06 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral arylpyridone derivatives |
| SG172778A1 (en) | 2008-12-22 | 2011-08-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| KR20110122874A (ko) | 2009-03-06 | 2011-11-11 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| CA2753825C (en) * | 2009-03-24 | 2017-10-17 | Abbott Laboratories | Process for preparing substituted pyrimidine antiviral compound |
| EP2421831A1 (en) * | 2009-04-25 | 2012-02-29 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| TWI428332B (zh) | 2009-06-09 | 2014-03-01 | Hoffmann La Roche | 雜環抗病毒化合物 |
| CA2762675A1 (en) | 2009-06-24 | 2010-12-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compound |
| CN102498100A (zh) | 2009-09-21 | 2012-06-13 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒杂环化合物 |
| PH12012500827A1 (en) | 2009-10-30 | 2013-01-07 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| CA2778206A1 (en) * | 2009-11-21 | 2011-05-26 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US20130029904A1 (en) * | 2009-12-18 | 2013-01-31 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| MX2012014235A (es) * | 2010-07-07 | 2013-01-28 | Hoffmann La Roche | Compuestos hetericiclicos antiviricos. |
| CR20180412A (es) | 2010-07-16 | 2018-11-01 | Abbvie Ireland Unlimited Co | Proceso para preparar compuestos antivirales |
| EP3461556A1 (en) | 2010-07-16 | 2019-04-03 | AbbVie Ireland Unlimited Company | Phosphine ligands for catalytic reactions |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| US9248193B2 (en) * | 2011-03-18 | 2016-02-02 | Abbvie Inc. | Formulations of phenyl uracil compounds |
| US8989328B2 (en) * | 2013-03-14 | 2015-03-24 | Qualcomm Incorporated | Systems and methods for serial communication |
| EP3043803B1 (en) | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| CN106065009B (zh) * | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US11026958B2 (en) | 2016-11-01 | 2021-06-08 | Merck Sharp & Dohme Corp. | Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
| US11613543B2 (en) | 2018-03-26 | 2023-03-28 | Novartis Ag | Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| EP4031247A1 (en) * | 2019-09-16 | 2022-07-27 | Novartis AG | Bifunctional degraders and their methods of use |
| EP4032006A4 (en) | 2019-09-16 | 2022-11-23 | Visa International Service Association | SYSTEM, METHOD AND COMPUTER PROGRAM PRODUCT FOR VERIFYING A MAP IMAGE |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111018910A (zh) * | 2019-12-05 | 2020-04-17 | 上海应用技术大学 | 一种铜催化合成含芳环α-羟基膦酸酯的方法 |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| CA2036304C (en) * | 1990-02-15 | 2001-04-17 | Takehiko Naka | Pyrimidinedione derivatives, their production and use |
| NL9001075A (cg-RX-API-DMAC7.html) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| CZ303435B6 (cs) | 1999-12-06 | 2012-09-12 | F. Hoffmann-La Roche Ag | 4-Pyrimidinyl-N-acyl-1-fenylalanin, meziprodukt pro jeho prípravu a farmaceutická kompozice |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| IL167955A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | Inilines are converted by troiril |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| CN101918369B (zh) | 2007-09-17 | 2016-02-24 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| RU2014147354A (ru) | 2007-09-17 | 2015-07-10 | Эббви Бахамаз Лтд. | Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения |
| NZ600371A (en) | 2007-09-17 | 2014-07-25 | Abbvie Bahamas Ltd | Uracil or thymine derivative for treating hepatitis c |
| WO2010010017A1 (en) | 2008-07-23 | 2010-01-28 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
-
2008
- 2008-09-17 CN CN200880116208.2A patent/CN101918369B/zh not_active Expired - Fee Related
- 2008-09-17 CN CN201610091594.0A patent/CN105693626A/zh active Pending
- 2008-09-17 EP EP11163527A patent/EP2377854A1/en not_active Withdrawn
- 2008-09-17 RU RU2010114826/04A patent/RU2542099C2/ru active
- 2008-09-17 HR HR20110632T patent/HRP20110632T1/hr unknown
- 2008-09-17 CA CA2699989A patent/CA2699989C/en not_active Expired - Fee Related
- 2008-09-17 EP EP12185550A patent/EP2548873A1/en not_active Withdrawn
- 2008-09-17 AT AT08831558T patent/ATE512954T1/de active
- 2008-09-17 JP JP2010525104A patent/JP5726527B2/ja active Active
- 2008-09-17 EP EP08831558A patent/EP2203430B1/en not_active Not-in-force
- 2008-09-17 WO PCT/US2008/076594 patent/WO2009039135A1/en not_active Ceased
- 2008-09-17 PL PL08831558T patent/PL2203430T3/pl unknown
- 2008-09-17 MX MX2010002904A patent/MX2010002904A/es active IP Right Grant
- 2008-09-17 CN CN201510508424.3A patent/CN105294569A/zh active Pending
- 2008-09-17 US US12/212,315 patent/US8178548B2/en active Active
- 2008-09-17 PT PT08831558T patent/PT2203430E/pt unknown
- 2008-09-17 DK DK08831558.5T patent/DK2203430T3/da active
-
2010
- 2010-04-16 ZA ZA2010/02690A patent/ZA201002690B/en unknown
-
2012
- 2012-04-06 US US13/441,528 patent/US8986740B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2699989C (en) | 2014-03-25 |
| US20120189580A1 (en) | 2012-07-26 |
| US20090176784A1 (en) | 2009-07-09 |
| JP2010539188A (ja) | 2010-12-16 |
| EP2203430A1 (en) | 2010-07-07 |
| RU2542099C2 (ru) | 2015-02-20 |
| PT2203430E (pt) | 2011-09-02 |
| CN101918369B (zh) | 2016-02-24 |
| CN105693626A (zh) | 2016-06-22 |
| JP5726527B2 (ja) | 2015-06-03 |
| US8986740B2 (en) | 2015-03-24 |
| MX2010002904A (es) | 2010-06-02 |
| CN101918369A (zh) | 2010-12-15 |
| WO2009039135A1 (en) | 2009-03-26 |
| DK2203430T3 (da) | 2011-09-26 |
| CN105294569A (zh) | 2016-02-03 |
| EP2203430B1 (en) | 2011-06-15 |
| HRP20110632T1 (hr) | 2011-10-31 |
| EP2377854A1 (en) | 2011-10-19 |
| RU2010114826A (ru) | 2011-10-27 |
| US8178548B2 (en) | 2012-05-15 |
| PL2203430T3 (pl) | 2011-12-30 |
| ATE512954T1 (de) | 2011-07-15 |
| CA2699989A1 (en) | 2009-03-26 |
| EP2548873A1 (en) | 2013-01-23 |
| HK1145839A1 (en) | 2011-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201002690B (en) | N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors | |
| MX2011009644A (es) | Inhibidores del virus de la hepatitis c. | |
| MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
| MX2013002927A (es) | Inhibidores del virus de la hepatitis c. | |
| MX2009004888A (es) | Inhibidores del virus de la hepatitis c. | |
| UA100840C2 (ru) | Композиция для лечения вирусного гепатита | |
| MX2009004943A (es) | Inhibidores del virus de la hepatitis c. | |
| MX2010008699A (es) | Derivados heterociclicos como inhibidores de virus de la hepatitis c. | |
| MX2012004032A (es) | Compuestos para el tratamiento de hepatitis c. | |
| MX2010008531A (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| MX2010001733A (es) | Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis. | |
| BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
| MX2009008439A (es) | Nuevos inhibidores de la replicacion del virus de hepatitis c. | |
| MX2010008749A (es) | Inhibidores del virus de la hepatitis c. | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| PL1987038T3 (pl) | Inhibitory HCV NS5B | |
| NZ595186A (en) | Di-pyrazolidinyl-biphenylyl compounds for treating hepatitis C virus (HCV) infection | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| WO2008021936A3 (en) | Hepatitis c virus inhibitors | |
| MX2010001416A (es) | Compuesto para el tratamiento de la hepatitis c. | |
| ATE547103T1 (de) | Hemmer des hepatitis-c-virus | |
| IN2012DN01855A (cg-RX-API-DMAC7.html) | ||
| MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
| TW200745004A (en) | Novel compounds, their preparation and use | |
| DE602008004317D1 (de) | Verbindungen zur behandlung von hepatitis c |